REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis study tested a combination of pembrolizumab (an immunotherapy drug) and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer bet…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug combo shows promise for tough lymphomas
Disease control CompletedThis early-phase trial tested the safety and best dose of olaparib combined with high-dose chemotherapy in 50 adults with lymphomas that returned or didn't respond to treatment. Participants received the drug combo before a stem cell transplant. The goal was to see if adding olap…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:38 UTC